Jacques Galipeau | Immunology and Microbiology | Research Excellence Award

Dr. Jacques Galipeau | Immunology and Microbiology | Research Excellence Award

University of Wisconsin-Madison | United States

Dr. Jacques Galipeau is a leading translational immunologist recognized for seminal contributions to mesenchymal stromal cell (MSC) biology, immune modulation, and engineered cytokine therapeutics. His research has reshaped global understanding of MSC immunogenicity, functional potency, and clinical limitations, directly influencing regulatory science and advanced cell therapy development. He pioneered the discovery and translation of fusokines, a novel class of synthetic cytokines with applications in autoimmunity, cancer immunotherapy, transplantation tolerance, and regenerative medicine. His work bridges mechanistic immunology and first-in-human translation, with sustained impact across academia and clinical development. According to Google Scholar, Dr. Jacques Galipeau has authored 478 peer-reviewed publications, received 23244 citations, and holds an h-index exceeding 71, reflecting sustained global influence.

                        Citation Metrics (Google Scholar)

30000

25000

20000

15000

10000

5000

0

 

Citations
23444
Documents
478
h-index
71

Citations

Documents

h-index

View Google Scholar Profile

Featured Publications


Mesenchymal stromal cells: clinical challenges and therapeutic opportunities

– J. Galipeau, L. Sensébé · Cell Stem Cell, 2018 · Cited by 1868


Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages

– J.S. Wang, D. Shum-Tim, J. Galipeau et al. · J Thorac Cardiovasc Surg, 2000 · Cited by 976


Mesenchymal stem versus stromal cells: ISCT® position statement on nomenclature

– S. Viswanathan, Y. Shi, J. Galipeau et al. · Cytotherapy, 2019 · Cited by 866

Human MSC suppression correlates with cytokine-induced IDO and M2 macrophage differentiation

– M. François, R. Romieu-Mourez, M. Li, J. Galipeau · Molecular Therapy, 2012 · Cited by 862

Allogeneic marrow stromal cells are immune-rejected by MHC-mismatched recipients

– N. Eliopoulos, J. Stagg, L. Lejeune et al. · Blood, 2005 · Cited by 700

Ying Cui | Immunology and Microbiology | Excellence in Research Award

Ms. Ying Cui | Immunology and Microbiology | Excellence in Research Award

Beijing Friendship Hospital, Capital Medical University | China

Ms. Ying Cui is an emerging neuroscientist whose research advances the understanding of the gut–brain axis, neurodegeneration mechanisms, and biomarker innovation in Parkinson’s disease (PD). Her work integrates metagenomics, multi-parameter clinical imaging, molecular neuroscience, and machine-learning analytics to improve diagnostic precision and support translational therapeutic development. With 6 Scopus-indexed publications, 85 citations, and an h-index of 2, her research impact continues to grow across both clinical and experimental domains. Ms. Ying Cui has contributed to high-value research projects, including multicenter clinical trials and national-level neuroscience studies, where she played key roles in microbiome profiling, experimental methodology, and advanced neuroimaging assessment using ¹²³I-MIBG scintigraphy. Her first-author publications provide novel insights into the diagnostic performance of cardiac and extra-cardiac washout rate parameters for differentiating PD from Parkinson-plus syndromes, offering clinically relevant imaging markers for complex diagnostic scenarios. Complementing her imaging research, Ying has developed a high-accuracy metagenomic diagnostic model with 99% validation accuracy and identified functional probiotic strains with the potential to modulate α-synuclein aggregation, mitochondrial dysfunction, and neuroinflammatory signaling work that has led to a PCT international patent for a probiotic composition targeting REM Sleep Behavior Disorder. Her multidisciplinary contributions span biomarker discovery, clinical–computational integration, translational microbiome innovation, and cross-institutional collaborations in neurology, microbiology, metabolomics, and bioinformatics. Through this synergistic research portfolio, Ying Cui continues to advance early diagnostic strategies, mechanistic insights, and therapeutic innovation in Parkinson’s disease, establishing herself as a rising researcher in translational neurodegeneration science.

Profiles: Scopus | ORCID

Featured Publications

  • Xue, T., Cui, Y., Kan, Y., & Yang, J. (2025). Value of extra-cardiac sympathetic nervous uptake parameters based on ¹²³I-MIBG SPECT/CT in the assessment of Parkinson’s disease. Clinical and Translational Imaging.

  • Xue, T., Cui, Y., Kan, Y., & Yang, J. (2025). Value of multi-parameter ¹²³I-MIBG scintigraphy in the differential diagnosis of Parkinson’s disease. EJNMMI Research.

Yun zou | Microbiology | Best Researcher Award

Mr. Yun zou | Microbiology | Best Researcher Award

The General Hospital of Western Theater Command | China

Zou Xinyun is a Master’s degree candidate and Chief Technician with a strong background in oncology and biomedical engineering. Since graduating from Hubei University of Science and Technology in 2011, he has been dedicated to medical research and clinical practice at the General Hospital of the Western Theater Command of the Chinese People’s Liberation Army. Currently, he is pursuing his Master’s degree in Biomedical Engineering at the School of Medicine, Southwest Jiaotong University, under the guidance of Professor Zhang Ling. His research contributions have been recognized through multiple prestigious awards and numerous scientific publications.

Profile👤

ORCID

Strengths for the Awards✨

  • Extensive Research Contributions 📚

    • Zou Xinyun has published five SCI papers as the first author in reputable journals, including Translational Cancer Research, Discover Oncology, and Clinical and Experimental Hypertension.
    • He has also co-authored several other publications, demonstrating his active involvement in collaborative research.
  • Academic Excellence & Recognition 🎓

    • He is a National Graduate Scholarship recipient, which highlights his academic excellence and dedication to research.
    • Recognized as an Outstanding Graduate of Hubei University of Science and Technology and an Excellent Medical Worker at his hospital, indicating his exceptional contributions to both research and clinical practice.
  • Strong Clinical and Research Background 🏥

    • With over a decade of experience at the Department of Oncology in a leading military hospital, he has gained deep expertise in clinical oncology research.
    • His ongoing Master’s in Biomedical Engineering at Southwest Jiaotong University under Professor Zhang Ling demonstrates a strong interdisciplinary approach to cancer research.
  • Zou Xinyun has an impressive research profile, particularly in oncology and biomedical engineering, with multiple SCI-indexed publications, academic excellence awards, and clinical research experience. While he is a strong candidate for the Best Researcher Award, focusing on high-impact publications, independent funding, and broader collaborations could further solidify his position as a top-tier researcher in his field.

🎓 Education

  • Bachelor’s Degree (2011) – Hubei University of Science and Technology
  • Master’s Degree Candidate (2021–2024) – School of Medicine, Southwest Jiaotong University
    • Research supervised by Professor Zhang Ling
    • Specializing in Biomedical Engineering

🏥 Experience

  • 2011–Present: Chief Technician, Department of Oncology, General Hospital of the Western Theater Command, Chinese People’s Liberation Army
    • Over a decade of experience in oncology research and clinical applications
    • Involved in advanced medical diagnostics and cancer treatment strategies

🔬 Research Interests On Microbiology

Zou Xinyun’s research focuses on oncology, biomedical engineering, and clinical cancer treatment. His work explores innovative approaches in cancer diagnostics, therapeutic interventions, and biomedical applications to improve patient outcomes. He is particularly interested in translational cancer research and the development of novel treatment methodologies.

🏆 Awards & Honors

  • 🏅 Outstanding Graduate – Hubei University of Science and Technology
  • 🏅 Excellent Medical Worker – General Hospital of the Western Theater Command
  • 🏅 National Graduate Scholarship – Recognized for academic excellence and research contributions

📚 Publications

  • Title: Association between immune cells and endometrial cancer: A bidirectional Mendelian randomization study

    • Authors: Xinyun Zou, Jinlan Shen, Hengdi Zhang, Fangyuan Kong, Xuemei Jin, Ling Zhang
    • Year: 2024
    • Citations: Not provided
  • Title: The causal effects of immune cells on pancreatic cancer: A 2‑sample Mendelian randomization study

    • Authors: Zou X, Shen J, Yong X, Diao Y, Ling Zhang
    • Year: 2024
    • Citations: Not provided
  • Title: Emodin ameliorates myocardial fibrosis in mice by inactivating the ROS/PI3K/Akt/mTOR axis

    • Authors: Huang W, Zhou P, Zou X, Liu Y, Zhou L, Zhang Y
    • Year: 2024
    • Citations: Not provided
  • Title: Radiomics in Nasopharyngeal Carcinoma

    • Authors: Wenyue Duan, Xiong B, Tian T, Zou X, He Z, Ling Zhang
    • Year: 2022
    • Citations: Not provided

🔚 Conclusion

Zou Xinyun is a dedicated researcher and medical professional with a strong commitment to oncology and biomedical engineering. His contributions to cancer research, coupled with his clinical expertise, have earned him significant recognition in the medical field. With a solid track record of academic excellence, professional experience, and impactful publications, he continues to advance medical science and improve patient care.